Drug Regulation, Treatment, and Public Order

Position

Define success without choosing a drug-war tribe

Drug policy succeeds when fewer people die, develop severe substance-use disorders, suffer violence or poisoning, drive impaired, lose years to incarceration, or find shared space controlled by dangerous conduct. It succeeds when people who want help can obtain treatment before motivation, insurance, housing, or life collapses. It succeeds when adults retain meaningful autonomy and children are protected from industries that learn to monetize compulsion.

No single measure can represent those outcomes. Arrest counts can rise while harm rises. Treatment enrollment can grow while retention and survival fall. Overdose deaths can decline while stimulant- related disability, public use, or alcohol harm worsens. Cannabis tax revenue can grow because heavy use grows. A balanced drug-policy ledger should track mortality, nonfatal overdose, substance- use disorder, treatment need and access, retention, emergency care, infectious disease, violence, impaired driving, public complaints, illicit-market share, youth use, product potency, criminal- justice contact, record relief, and neighborhood conditions.

The policy should separate six categories that prohibition rhetoric often fuses:

1. Private adult use implicates autonomy, product risk, and health information.
2. Addiction implicates impaired agency, treatment, recovery support, and recurring risk.
3. Public conduct implicates other people's use of streets, transit, homes, work, and schools.
4. Impaired operation or caregiving imposes direct risk on other people.
5. Commercial supply creates duties involving product, marketing, age, tax, and market power.
6. Predatory supply involves deception, adulteration, coercion, violence, minors, or lethal products whose risk cannot support ordinary retail commerce.

A proportional system applies different tools to those categories. It does not need to deny that use can become illness, that illness can produce harmful conduct, or that a person who commits harm still has a health need. Multiple facts can be true, and each can justify a different public duty.

Cannabis should leave federal prohibition

The federal-state cannabis conflict is not a stable compromise. States authorize adult and medical markets while federal law continues to treat marijuana as Schedule I. Businesses operate under state licenses but face federal tax, banking, bankruptcy, research, firearms, immigration, and criminal-law consequences. Consumers encounter products that cross state regulatory systems without a common national floor. Prosecutorial discretion has shifted across administrations.

In May 2024, the Department of Justice proposed moving marijuana from Schedule I to Schedule III. The proceeding was delayed and restarted, with a formal hearing beginning in June 2026. The live status matters: cannabis had not simply become federally legal. Schedule III would still regulate manufacture and distribution through the Controlled Substances Act and would not authorize state adult-use commerce as such.

Congress should remove cannabis from the Controlled Substances Act and enact a federal adult-use framework. Descheduling is a conclusion about the proper legal regime, not a claim that cannabis is harmless. Alcohol and nicotine show why legal status must carry strong public-health rules. The goal is a regulated market that displaces illicit supply without optimizing heavy consumption.

Federal law should set minimum age 21 for nonmedical sale, product-testing standards, contaminant limits, ingredient and active-content disclosure, child-resistant packaging, marketing limits, tax administration, interstate tracking, labor and environmental duties, anti-diversion controls, and research access. States may prohibit sale, limit form and potency, set local hours and density, operate public or nonprofit distribution, or impose stronger rules. Tribal nations should possess clear authority over commerce in their jurisdictions under a negotiated federal framework.

Medical cannabis needs a transition rather than a slogan. Some state programs serve patients whose products or indications lack the evidence and manufacturing consistency expected of FDA-approved medicines. Others provide access where standard products have failed. Congress should protect current patients during a phased system, fund trials and product characterization, preserve a state medical route under minimum safety rules, and encourage FDA applications where a specific product and indication can meet evidence standards. “Medical” should not be a pretext for adult sale, and FDA exclusivity should not abruptly remove patient access to every botanical product.

Product rules should follow form and dose

Cannabis regulation should not treat flower, high-potency concentrate, edible candy, beverage, inhaled oil, and topical product as interchangeable. Onset, duration, dosing error, contaminant pathway, appeal to children, and acute impairment differ. The federal floor should require a standard unit or clearly labeled active-content measure, but regulators should test whether consumers understand it and whether manufacturers game it through serving size.

Edibles need per-serving and per-package limits, individual marking where feasible, delayed-onset warnings, and packaging that cannot be confused with ordinary candy or snacks. Inhaled products need ingredient restrictions, emissions and contaminant testing, hardware safety, and traceability. Concentrates may justify higher age, dose, or tax rules if evidence shows disproportionate risk. Claims about relaxation, sleep, anxiety, focus, or pain should be regulated according to whether they are ordinary descriptions, health claims, or treatment claims.

Testing laboratories need blind proficiency samples, conflict rules, method standards, and public discipline. A licensed market can still create “lab shopping” if producers reward the highest potency result or the easiest contaminant pass. Regulators should publish lab-level anomalies and retain reference testing capacity. Product recalls should travel through an interoperable system to retailers and consumers without building a registry of individual use.

Packaging should communicate risk without becoming moral theater. A short front label can state active content, serving, onset, impairment, age, pregnancy, and child-safety information, with a QR or accessible link for fuller evidence. Warnings should be periodically tested for comprehension and behavior. A wall of legally defensive text that nobody reads is not disclosure.

Marketing and market structure

A legal industry will seek repeat customers and growth. For a potentially dependence-forming product, ordinary engagement optimization can conflict with public health. Cannabis advertising should not target minors, use cartoon or child-associated design, make unsupported therapeutic claims, promote driving or high-risk combination, or use sensitive behavioral data to identify people showing signs of problematic use.

Federal rules should restrict paid placement near schools and youth media, require age-gated direct marketing, disclose sponsorship and paid influence, and prohibit loyalty systems designed around escalating dose or frequency. States may adopt plain-packaging or public-retail experiments. Political speech by firms remains protected; commercial claims about product and health receive ordinary consumer-protection scrutiny.

License design should prevent both illicit persistence and corporate capture. Fees and compliance should be scaled so a safe small operator can enter. Technical assistance, cooperative finance, and access to compliant premises may do more than a paper preference for applicants harmed by prohibition. Ownership and beneficial interests should be transparent to regulators. Vertical integration and outlet concentration should face review where they undermine competition or make public health dependent on a few firms.

The platform should not promise that legalization automatically produces racial or economic repair. Prior enforcement harmed people through records, incarceration, lost work, family separation, and asset loss. Automatic record relief and reinvestment are direct mechanisms. A license lottery with no capital, lease, compliance, or market access can turn repair into another speculative asset.

Tax without addiction finance

Cannabis tax must balance four purposes: fund regulation; internalize public-health and safety costs; support treatment, research, and record repair; and leave enough lawful-market share to displace illicit supply. Excess tax can sustain illegal sellers and untested product. Low tax can encourage high-potency consumption and leave public costs unpaid.

A hybrid structure can tax active content or potency bands plus a retail component. Regulators should study measurement error, product substitution, and consumer response before declaring the formula settled. Local governments hosting outlets may receive revenue for inspection and public services. A stable share should fund independent research and treatment rather than annual appropriations that disappear when attention moves.

Revenue projections should use declining or stable consumption scenarios as well as growth. No school, transit system, or general budget should depend on selling more intoxicant. Earmarks can also fragment budgets and protect ineffective programs. Fund defined duties and require public outcome reports rather than treating the source of money as proof of program value.

Impairment, driving, and safety-sensitive work

Legalization must not weaken the rule against operating a vehicle, aircraft, train, heavy machine, weapon, or safety-critical system while impaired. The hard question is evidence. Alcohol's per se concentration framework does not transfer cleanly to cannabis because measured metabolites and impairment relationships differ by product, route, time, and user.

Law should authorize stops based on ordinary reasonable suspicion, standardized observation, properly validated field methods, and confirmatory testing where material. A biological threshold may contribute to evidence if science supports it; it should not be selected for political simplicity and described as equivalent to blood alcohol. Defendants need access to methods, calibration, samples where feasible, and expert challenge.

Road-safety agencies should fund prospective research, simulated and on-road validation under safe conditions, crash epidemiology, and evaluation of combined alcohol and cannabis use. Public campaigns should state that legal purchase is not legal impaired driving and that combining intoxicants can increase risk. Ride, designated-driver, and transit options should accompany enforcement.

Employers may prohibit possession and impairment at work and set defensible rules for safety- sensitive roles. They should not infer current impairment solely from a test that detects earlier lawful off-duty use when the job and law do not justify that inference. Federal contractors and regulated industries need updated rules after descheduling. Disability and medical-use claims should receive individualized analysis subject to safety.

Automatic record repair

Legal reform is incomplete if old possession records continue to block housing, work, education, licenses, credit, or family stability. Federal courts and agencies should automatically seal or expunge eligible simple-cannabis-possession records and correct background systems. People should not need to discover eligibility, hire counsel, pay a fee, or prove rehabilitation for conduct the law no longer criminalizes.

Sentence review should identify people incarcerated or supervised solely for newly lawful conduct. Where a sentence combined eligible and ineligible counts, a court should determine the effect under a clear standard. Relief should not erase violence, coercion, weapons conduct, sales to minors, impaired driving, or independent trafficking. Prosecutors should bear the burden of identifying a specific disqualifying record rather than relying on an opaque case label.

States need grants, data standards, and deadlines to automate relief. Courts, corrections, police, repositories, licensing agencies, and commercial background firms must receive corrections. A public dashboard should show eligible cases, completed relief, unresolved records, time, and error, with individual identity protected. A court order that never reaches a background database is nominal repair.

Revenue from regulated cannabis can support legal aid and economic repair, but relief should not depend on sales growth. Congress can fund it as a justice obligation. People whose conduct remains illegal deserve ordinary due process and proportionate sentencing; legalization should not become a pretext for escalating punishment of the remaining illicit market without regard to violence, role, and culpability.

Personal possession of other drugs

Federal and state law should remove criminal penalties for possession of a defined small amount for personal use. The law should authorize confiscation and a civil health-and-safety response. It should not authorize commercial production or sale. Decriminalization changes the legal treatment of the user, not the risk classification of the supply.

Threshold design needs more care than a uniform weight table. Fentanyl potency makes mixture weight a poor proxy for doses or role. Packaging, cash, communications, scales, repeated transactions, weapons, witness evidence, and actual conduct may support distribution. Quantity can remain evidence, especially at large scale, but a threshold should create a rebuttable personal-use safe harbor or presumption rather than allow prosecutors to turn trace fentanyl in a mixture into a mandatory trafficking sentence.

The civil response should avoid a ladder of punishment. A small fine that becomes fees, warrant, license suspension, contempt, and jail is criminalization by installment. Confiscation, a no-cost assessment offer, scheduled appointment, transportation, and follow-up are more aligned. For a person without evidence of disorder, voluntary health information may be sufficient. For someone with repeated overdose or visible addiction, assertive voluntary engagement should intensify.

Mandated treatment can be justified as a condition of diversion after conduct that would otherwise support a proportionate criminal sanction, or through the narrow grave-danger process in HEALTH-05. Possession alone should not create open-ended treatment coercion. A person can comply performatively, displace another patient, or be confined in a low-quality program that calls itself care. Every mandated program needs clinical standards, medication access, grievance, time limit, and judicial review.

Oregon's warning without a false causal story

Oregon voters approved decriminalization through Measure 110, and the state later revised the law through House Bill 4002, effective in 2024, recriminalizing possession under defined conditions and creating deflection pathways. The episode is cited by opponents as proof that decriminalization fails and by supporters as proof that implementation was undermined. Neither slogan substitutes for causal analysis.

The relevant questions include treatment capacity and timing, outreach, citation uptake, fentanyl's arrival, housing and homelessness, public-use rules, police practice, local variation, pandemic effects, overdose trends in comparison states, and what residents experienced. A state can have a principled distinction between possession and predation and still design a weak referral, move too slowly, or lose public consent when visible disorder grows.

The Innovation Party learns four lessons. Decriminalization and treatment capacity should begin together. The referral must schedule care rather than merely offer a number. Public-use and dealing rules must be explicit and enforceable. Statute should include a dashboard, local implementation review, and revision triggers before crisis politics forces an all-or-nothing reversal.

Oregon's change also shows that democratic policy can bend. Revising a mechanism is not betrayal if the legislature states which outcome failed and preserves the moral distinction it can still defend. The party should not promise never to change a threshold. It should promise not to use failed administration as an excuse to return personal possession to the center of punishment.

Treatment capacity on a clock

SAMHSA's 2024 National Survey on Drug Use and Health estimated that 52.6 million people age 12 or older met its definition of needing substance-use treatment. About 10.2 million received treatment, 19.3 percent of those classified as needing it. Survey estimates exclude some institutionalized populations and depend on definitions and self-report, but they establish a national access gap large enough to shape legal design.

A referral must include a service time. Following overdose, emergency department, EMS, police, fire, or an overdose-prevention provider should initiate medication where authorized, provide naloxone, and make a warm handoff. Follow-up should occur within 72 hours. An urgent person should receive clinical assessment within seven days and routine care within 30. Health plans and public systems that miss the clock should pay for qualified out-of-network or regional care at no extra patient cost.

Care capacity includes outpatient and inpatient treatment, office and community medication, withdrawal management, stabilization, residential care when clinically necessary, recovery housing, peer services, transport, childcare, and telehealth backed by in-person options. Rural areas need mobile and hub-and-spoke models. Jails and prisons need continuation and initiation of medication, naloxone at release, records transfer, and scheduled community follow-up.

Workforce policy should expand addiction-medicine training, nursing, counseling, social work, peer credentials, pharmacy roles, and primary-care integration. Scope changes should follow competence and supervision, not professional turf. Payment should cover care coordination and outreach that fee-for-service medicine often leaves unpaid.

Medications and recovery pluralism

Medication for opioid-use disorder is a central evidence-based treatment. CDC states that medication treatment is associated with lower overdose and overall mortality and recommends that clinicians offer or arrange it. Detoxification without medication is not recommended because of the increased risk of resumed use, overdose, and death.

Public systems should remove arbitrary prior authorization, dosage interference, counseling prerequisites unsupported by evidence, and blanket exclusions. Methadone, buprenorphine, and naltrexone have different delivery, risks, and patient fit. Policy should expand access while maintaining diversion, quality, and safety controls proportionate to each medication.

Alcohol-use disorder also has approved medications and behavioral treatments. Stimulant-use disorder lacks an equivalent broadly approved medication, which increases the importance of contingency management and research. Public coverage should reimburse evidence-based contingency management within fraud-resistant program rules rather than reject it because the intervention uses tangible incentives.

Recovery communities offer meaning, accountability, identity, relationships, and hope. Public policy should support plural voluntary models, including abstinence-oriented and faith-based services, when they meet safety, nondiscrimination, transparency, and clinical referral duties. A faith-based provider should not be forced to abandon its message, and a patient should not lose access to medication or public benefits because of that provider's theology. Conscience belongs to both, with an equivalent service path.

Outcome measures should not define success solely as abstinence or solely as survival. Survival is foundational. Reduced dangerous use, health, housing, family stability, education, work, legal involvement, and patient-defined recovery matter. Programs should disclose which population and goal they serve so results are not generalized beyond the model.

Naloxone and overdose response

In 2024, the National Vital Statistics System counted 79,384 drug-overdose deaths, including 54,045 involving an opioid and 47,735 involving synthetic opioids other than methadone. The totals were lower than the prior peak but still represent a massive preventable loss. Decline should prompt analysis of what changed, not withdrawal of overdose response.

Naloxone is an opioid antagonist that reverses overdose and has no abuse potential. FDA approved the first over-the-counter naloxone nasal spray in 2023. Federal and state programs should use bulk purchase, standing orders where needed, insurer coverage, vending, mail, and community distribution to make price and geography less decisive.

Settings should be selected through risk: people prescribed high-dose opioids or using illicit opioids, family and peers, people leaving incarceration or treatment, shelters, libraries, transit, schools and colleges, venues, first responders, construction and other high-risk workplaces, and rural communities with long EMS times. Distribution should not require the recipient to register as a drug user.

Training should cover recognition, emergency call, rescue breathing as appropriate, administration, repeat dosing, and the need to stay until help arrives. Programs should measure kits distributed, availability, reported reversals, replacement, expiration, price, and geographic coverage without making rescue contingent on data surrender.

Good Samaritan law should protect the caller and overdose victim from possession and paraphernalia charges arising from the request for aid. Protection should also cover reasonable probation or parole technical consequences tied solely to the discovered use where legally feasible. It need not shield violence, an outstanding serious warrant, child abuse, weapons offenses, or independent evidence of trafficking. The exception must be narrow enough that people can understand the promise.

Syringe, drug-checking, and wound-care services

Sterile syringe programs reduce reuse and create access to HIV and hepatitis testing, vaccination, safe disposal, naloxone, wound care, and treatment. Their value depends on comprehensive operation. A box of supplies without disposal, outreach, and service linkage is not the full intervention.

Programs should publish distribution and return or disposal measures with context. A strict one-for- one exchange can deny sterile equipment to people at highest risk and encourage reuse. Unlimited distribution without neighborhood disposal capacity can create visible litter and political failure. Mobile pickup, disposal kiosks, participant education, and rapid response around sites can protect both goals.

Drug checking can warn about fentanyl or other contents and supply public-health intelligence. Tests have limits, may sample only part of a product, and cannot certify safety. Programs should state sensitivity, false results, sampling limits, and what a result means. Aggregate alerts can be published without feeding an enforcement database of service users.

Wound and infection services should be easy to enter without surrendering to unrelated law enforcement. Serious threats, violence, and mandatory reporting remain governed by law. Medical privacy and trust are part of effectiveness because a service avoided through fear cannot reduce infection.

Supervised-consumption pilots

Supervised-consumption sites allow a person to consume pre-obtained drugs under observation, with overdose response and links to health and social care. The strongest immediate claim is bounded: staff can respond to an overdose that occurs on site. Studies also examine service uptake, unsafe use, ambulance calls, infection, public use, litter, crime, and population mortality.

A 2026 systematic review led by Public Health Agency of Canada researchers found mixed evidence on population-level overdose mortality. Some smaller-area studies found lower mortality after site implementation, while rigorous provincial comparisons found no difference. The review concluded that individual-level benefits are documented but population effects are context dependent and that more rigorous research is needed. A prior Stanford-Lancet Commission report available through CDC similarly stated that evidence had not established lower individual fatal-overdose risk over time or lower community overdose rates.

That evidence supports lawful pilots with humility. Congress should create a waiver or statutory path for state and local pilots that meet federal requirements, rather than force policy through uncertain litigation under drug-premises law. The site may not sell or supply illegal drugs. It must prevent dealing and coercion, maintain clinical protocols, train staff, stock reversal and medical equipment, protect privacy, and coordinate emergency response.

The operating agreement should include hours, capacity, exterior management, sanitation, discarded-equipment response, security, neighbor contact, complaint resolution, and a defined perimeter. The site should offer or schedule treatment and benefits without making service conditional on accepting them. Data should cover onsite overdoses and reversals, emergency transport, treatment linkage, repeat use, adverse events, participant survival where follow-up is ethical, public consumption, litter, calls, crime, business and resident experience, displacement, and cost.

A pilot needs a comparison and sunset. A matched area, staggered rollout, time-series design, or other credible method should be pre-specified. Results should distinguish site users from the whole population and immediate area from the city. If the site concentrates dealing, threats, or public use, or fails to reach people at risk, operators must change location, rules, services, or close. If it prevents on-site death and improves care without material neighborhood harm, law should permit continuation and replication.

Public use, disorder, and shared space

Possession decriminalization does not immunize conduct. Government may restrict smoking or intoxication in transit, schools, workplaces, playgrounds, entrances, and other places where use exposes people, blocks access, or creates danger. It may enforce impaired-driving law, child- endangerment law, assault, theft, threat, obstruction, fire, sanitation, and nuisance rules.

The response should be proportionate to act and risk. An adult discreetly possessing a personal amount calls for confiscation and health response. Someone using in a transit car after warning can be removed and cited. A person repeatedly blocking a business while intoxicated may require outreach, relocation, citation, or arrest if lawful orders fail. Violence or a lethal threat permits immediate police intervention. Addiction can explain conduct without making other people absorb it.

Cities need usable alternatives. Low-barrier shelter, sobering and stabilization, treatment intake, safe consumption where authorized, storage, sanitation, and transport give enforcement somewhere to direct a person. An “offer” must be open, accessible for disability, and reasonably matched to family, sex, safety, and service needs. It need not be the person's preferred permanent housing before every conduct rule can apply, but it must be more than a phone number or a full site.

Fines should not become unpayable debt. Community service may be inappropriate for an acutely ill person and exploitative if used without choice. Civil courts should be able to waive, convert, or close sanctions based on ability, treatment engagement, and repeated failure of government capacity. Arrest should address a real offense, danger, or lawful noncompliance, not the fact that a person is visibly addicted.

Trafficking, adulteration, and culpability

Criminal enforcement should focus on actors who create and profit from serious risk. Priority targets include fentanyl and methamphetamine manufacture and distribution, counterfeit pills, adulteration without disclosure, sales to minors, coercive dealing, violence, money laundering, corruption, and commercial-scale trafficking. International operations should focus on organizations, precursors, finance, equipment, and leadership while coordinating with public health to avoid sudden supply disruptions that increase poisoning.

Penalty should follow role, knowledge, intent, scale, violence, product, adulteration, and actual harm. A courier under coercion, low-level seller supporting addiction, organizer, violent enforcer, and chemist deliberately pressing fentanyl into counterfeit medicine are not equally culpable. Mandatory minimums can flatten those differences and transfer charging power from judges to prosecutors. JUS-01 supports judicial discretion and sentencing review.

“Drug-induced homicide” laws raise hard questions. A person who knowingly sells a lethal counterfeit pill or adulterates product can possess grave culpability. A friend who jointly uses and calls for help may be deterred from rescue by a sweeping homicide threat. Statutes should require a demanding mental state and causal proof, protect good-faith aid, and distinguish predatory sale from social sharing or shared use.

Enforcement metrics should not reward total seizures or sentence-years independent of harm. They should examine disrupted capacity, violence, poisoning, market replacement, price and purity, overdose, corruption, and whether another organization immediately fills the gap. A spectacular seizure can coexist with no durable public benefit.

Alcohol, tobacco, nicotine, and consistency

A coherent drug policy cannot speak only about illegal drugs. Alcohol contributes to impaired driving, violence, disease, family harm, and addiction. Tobacco remains a major source of preventable death. Nicotine vaping can reduce exposure for an adult smoker who switches completely while creating youth initiation and dependence risk. Legal status reflects history and culture as well as pharmacology.

The party applies the same risk-regulation principles. Adults may use legal products. Government may tax, label, restrict age and place, control marketing, enforce impaired operation, fund treatment, and regulate product. It should compare total risk and substitution rather than protect an incumbent product from a less harmful alternative or market a newer product as harmless.

Alcohol policy should strengthen responsible-service enforcement, treatment access, impaired- driving prevention, transparent labeling, and scrutiny of digital marketing to heavy users. Local outlet density and hours can be adjusted through evidence and due process. Criminal law targets dangerous conduct, not adult possession.

Tobacco and nicotine policy should prevent youth sale and marketing, support cessation, disclose product risk, and preserve a regulated pathway for adults who use lower-risk products to leave combustion. Flavor and product rules should evaluate youth uptake, adult switching, illicit markets, and enforcement equity. Industry claims require independent evidence.

This consistency answers a common fairness objection. Cannabis should not remain prohibited merely because alcohol is culturally established. Fentanyl should not receive a retail market merely because alcohol is legal. Similarity in one dimension does not erase difference in lethality, dependence, dosing, externality, or institutional capacity.

Psychedelic research and clinical pilots

Psychedelic research has expanded for depression, post-traumatic stress, substance-use disorders, and other conditions. The FDA's 2023 guidance explains why these trials present unusual design questions: obvious psychoactive effects can unblind participants and investigators; psychotherapy or support may be part of the intervention; abuse and safety need monitoring; dose response and durability matter.

Federal policy should remove research frictions unrelated to participant or diversion safety. Institutions need predictable DEA registration, secure supply, reference materials, investigator training, and grants for multi-site trials. Public funding is important where compounds are old, natural, or difficult to protect through ordinary intellectual property, because private incentives may otherwise favor proprietary variations rather than the most informative comparison.

Trials should pre-register endpoints and analysis, use credible controls or active comparators where possible, assess expectancy and blinding, distinguish drug from therapeutic support, and follow participants long enough to assess benefit, relapse, mania, psychosis, suicidality, cardiac events, persisting perception changes, and exploitation. Enrolling representative patients matters; so does excluding people whose risk makes a study unsafe.

FDA should apply the same statutory safety and effectiveness standard as for other drugs. It can accept a therapy model or risk-management program when evidence supports one. Approval of a specific formulation, dose, indication, and administration model should not be advertised as proof for another mushroom product, retreat, microdose subscription, or facilitator.

States may test supervised adult therapeutic-service models under federal permission. A pilot should screen medical and psychiatric risk, test product, license and background-check facilitators, require informed consent, set touch and sexual-boundary rules, provide emergency capacity, insure providers, log adverse events, protect records, bar outcome guarantees, and maintain a complaint and compensation path. Participants should know what is experimental and what evidence supports the claim.

General adult possession decriminalization can apply to a small psychedelic amount under the wider rule. That does not require a commercial market or clinical claim. The state can decline to criminalize the person while still enforcing unlicensed sale, adulteration, impaired driving, fraud, and unsafe provision.

Minors, pregnancy, and vulnerable users

Children and adolescents require a stronger protection model because developing judgment, peer influence, family context, and industry targeting change consent. Regulated cannabis, alcohol, nicotine, and psychedelic markets should use age verification that minimizes data, retailer enforcement, graduated license consequences, and penalties for adults who knowingly supply in dangerous circumstances. A minor should not receive an adult criminal record for possession.

Schools should use evidence-based prevention that teaches product, dose, impairment, addiction, marketing, emergency response, and help-seeking. Scare claims that students can disprove damage credibility. Normalizing use as inevitable also fails. Students need confidential routes to counseling with clear exceptions for imminent danger and abuse.

Pregnancy warnings should communicate evidence and support care without turning prenatal medicine into surveillance. Fear of prosecution can deter prenatal and addiction treatment. Providers should screen, counsel, and offer treatment under privacy rules. Conduct that independently meets child-protection law receives due process; a positive test alone should not become automatic proof of neglect without clinical and contextual assessment.

Older adults, people with cognitive disability, chronic pain patients, and people leaving incarceration or treatment may have heightened overdose or interaction risks. Product warnings and care should be accessible. Prescriber enforcement must coordinate with health agencies so a clinic closure does not abruptly abandon patients and trigger illicit-market exposure. CDC's Opioid Rapid Response Program recognizes the overdose danger created by care disruption.

Pain care and enforcement coordination

The response to prescription-opioid harm produced abrupt tapers and clinic disruptions for some patients with chronic pain. Drug policy should not assume that reducing a prescription count automatically improves health. Clinicians need evidence-based prescribing guidance, monitoring, consultation, and the ability to individualize care. Patients need notice, continuity, and a safe transition when a prescriber closes or loses authority.

Law enforcement should pursue pill mills, fraud, diversion, and knowing dangerous practice while coordinating with public health before an action that may interrupt controlled-substance care. The CDC's 2026 Opioid Rapid Response Program is designed to notify and help state authorities mitigate overdose risk when enforcement disrupts access. That coordination should be routine and evaluated.

Medical boards and payers should not convert dosage guidance into inflexible ceilings without individual review. At the same time, “patient abandonment” rhetoric cannot protect a provider who knowingly operates outside standards for profit. Independent clinical review, records, patient outcomes, prescribing pattern, financial incentives, and response to warning all matter.

Research and coverage for non-opioid pain treatment, physical and behavioral therapy, interventional care, and multidisciplinary programs should expand. Access must be real; denying one therapy while not covering alternatives transfers pain to the patient.

Privacy, data, and a non-surveillance treatment system

People avoid care if a treatment record becomes a generalized police, employment, housing, or family-surveillance record. Substance-use information requires strong privacy, consent, minimum- necessary sharing, security, and breach response. Clinical teams need lawful information flow for safe treatment, medication interaction, and emergency handoff. The design should distinguish care coordination from unrelated access.

Prescription drug monitoring programs can identify dangerous combinations, multiple prescribers, and possible diversion. They can also produce false suspicion and access barriers. Queries should be purpose limited and logged. Patients and clinicians should be able to correct errors. Algorithmic flags should support review, not automatically deny medicine or trigger investigation.

Harm-reduction and supervised-site data should use participant identifiers only when needed for care and evaluation, with separation from law enforcement absent a warrant, emergency, or specific legal duty. Aggregate public-health alerts can describe dangerous supply without exposing users. Research linkage should use consent, privacy-preserving methods, and independent governance.

Cannabis purchase systems should verify age and license compliance without building a national consumer registry. Loyalty and advertising data should face ordinary privacy and special sensitive- inference limits. Employers and insurers should not purchase inferred addiction profiles from data brokers.

Federalism and the national floor

States have generated much of the country's cannabis, decriminalization, harm-reduction, and psychedelic policy experimentation. Federal law should preserve bounded variation while resolving the incoherence it created. National floors are justified for interstate product, contaminants, marketing, research, civil rights, records, and trafficking. States and localities can choose retail models, outlet density, stronger product limits, pilot designs, and whether to authorize sale.

Federal descheduling should not require a state to permit cannabis stores. Interstate-commerce rules should prevent a prohibition state from controlling commerce elsewhere while preserving its ability to bar in-state sale and use subject to constitutional limits. State medical and adult systems need a transition period before interstate consolidation.

Possession decriminalization should establish a federal rule for federal law and incentives for states. Congress can condition justice and treatment grants, fund record repair, and create model thresholds while recognizing state criminal authority. Constitutional counsel should assess the limits of particular conditions.

Tribal nations should participate as governments, not be treated as local license applicants. Federal law should clarify jurisdiction, taxation, product movement, public health, and enforcement through consultation and compact options. Border communities need agreements that avoid turning jurisdictional uncertainty into selective enforcement.

Implementation sequence

The first package should combine cannabis regulation, possession reform, treatment capacity, overdose prevention, and enforcement priorities. Separating them invites failure: legalization without public health, decriminalization without treatment, treatment without access, or enforcement without a culpability rule.

Title I would deschedule cannabis, create the regulatory authority and standards process, preserve state choice, authorize compliant banking and tax treatment, and fund research. Title II would automate federal record relief and support state systems. Title III would remove criminal penalties for defined personal possession and establish health-centered civil response. Title IV would fund the treatment clock, medication, recovery services, naloxone, syringe and checking programs, and lawful local pilots. Title V would target adulteration, minors, violence, lethal trafficking, impaired operation, and organized finance with sentencing proportionality.

Regulators should publish interim product rules before interstate cannabis commerce. Existing state operators receive a compliance window. Lab proficiency and recall systems should begin early. Advertising and youth rules take effect before market expansion, not after firms establish brand and political power.

States accepting decriminalization funds should certify treatment availability by region, publish referral completion, and maintain public-conduct rules. A jurisdiction without capacity should receive build funding and a phased threshold, not permission to call a hotline a system.

Research waivers for supervised-consumption and psychedelic pilots should use common minimum data but permit local design. Independent evaluators should publish protocols before results. Null and negative findings receive the same release duty.

Revision rules

Cannabis rules should be reviewed on youth use, disorder, impaired driving, poisoning, product potency, illicit share, concentration, advertising, adult substitution from alcohol or tobacco, and tax dependence. If high-potency product drives disproportionate harm, limits or tax can tighten. If overregulation sustains unsafe illicit supply, barriers can fall. The adult legal status remains unless evidence supports a fundamentally different conclusion.

Possession thresholds should be reviewed for false trafficking charges, organized evasion, user behavior, overdose, and enforceability. Changing a number is not abandoning decriminalization. The burden is to explain which mechanism moved and why.

Treatment programs should be renewed based on access, retention, survival, health, patient experience, and equity, not ideology or enrollment alone. A provider that excludes medication must disclose its model and cannot be the only publicly funded path where medication is indicated.

Supervised-consumption pilots must change or close if exterior harm is unmanaged, dealing controls fail, emergency operations are unsafe, data are withheld, or benefits do not justify burden. They may expand when participant and neighborhood outcomes support it. Psychedelic pilots follow the same rule, with special attention to adverse events, exploitation, and unsupported claims.

Enforcement should be reviewed for displacement, violence, poisoning, corruption, and disparate impact. A strategy that produces long sentences for replaceable low-level actors without reducing lethal supply is failure even if seizures rise.

Principled Foundation

The position begins with adult agency bounded by harm to others. Government needs a strong reason to imprison a person for what the person privately possesses or consumes. Risk to the user can justify information, product regulation, tax, treatment availability, and some restrictions. It does not automatically justify a criminal record. Danger imposed on another person, predatory commerce, and exploitation of impaired agency justify stronger intervention.

Addiction complicates autonomy without erasing personhood. A substance-use disorder can narrow choice, reorder priorities, and persist despite catastrophic consequence. The humane response is not to pretend every act is fully free or that the person becomes an object government may control. Care should restore agency through accessible evidence-based help, stable conditions, relationships, and repeated opportunity. Coercion requires a separate lawful trigger and due process.

Equal citizenship rejects two hierarchies. A person who uses an illegal drug does not lose ordinary rights or the claim to rescue. A person who does not use drugs does not owe surrender of a transit car, doorway, park, workplace, or child's environment. Compassion cannot be financed by assigning unconsented disorder to neighbors with the least power to avoid it.

The anti-domination principle identifies predation across public and private power. A cartel, dealer who adulterates a pill, cannabis firm optimizing dependence, police unit using possession for arbitrary searches, fraudulent treatment center, and state that conditions care on humiliation can all dominate. The tool changes with the actor; the demand for limits and remedy does not.

Conscience permits voluntary recovery communities, including faith-based and abstinence-centered ones, while requiring an equivalent public path that does not impose belief or deny indicated medicine. No clinician should be forced to provide a service outside competence or serious ethical judgment, but the system owes timely information and referral.

Innovation is disciplined experimentation. Cannabis regulation should learn from states. Treatment should measure time and outcome. Harm-reduction pilots should include neighborhood effects. Psychedelic promise should move through interpretable trials. A failed mechanism changes. The person does not become disposable because a program failed.

Core Value Alignment

Technology for Human Welfare and Sustainability. Product testing, overdose reversal, medication, drug checking, interoperable referrals, and clinical research are used to keep people alive and restore health. Technology does not excuse coercion or inflated claims.

Privacy, Security, and Trust. Adults retain private autonomy while public rules address impaired driving, dangerous conduct, and predation. Treatment, prescription, purchase, and harm-reduction data receive purpose limits. Trust grows when rescue does not become a possession trap.

Inclusive Growth and Economic Development. Criminal records, illness, death, caregiver burden, unsafe streets, and predatory markets remove people and places from economic life. Record relief, treatment, recovery, and usable public space expand participation. Legal cannabis faces competition and labor rules rather than becoming a protected oligopoly.

Research, Innovation, and Collaboration. FDA trials, state pilots, national statistics, pre-registered evaluation, adverse-event reporting, and revision rules replace factional certainty. Researchers, patients, families, clinicians, recovery communities, police, residents, businesses, and tribal governments all hold relevant knowledge.

Education and Digital Literacy. People need accurate information about dose, onset, impairment, addiction, interactions, overdose, rescue, marketing, and evidence. Youth prevention should be credible enough to survive contact with experience. Clinicians and justice officials need training to interpret tests and data rather than overclaim them.

Access to Information and Connectivity. Treatment availability, wait times, product recalls, market ownership, enforcement outcomes, pilot results, and dangerous-supply alerts should be findable. Individual medical and use records remain protected. Public knowledge is not a license for personal exposure.

The values align because autonomy without safety can become abandonment, safety without autonomy can become carceral control, innovation without evidence can become hype, and treatment without access can become a sentencing euphemism.

Party Comparison

The 2024 Democratic platform supports marijuana reform, expungement, treatment, overdose prevention, and criminal-justice change. Its coalition contains strong harm-reduction and legalization voices. The exposure is reluctance to define public-order enforcement and the legal boundary between decriminalization and commercialization of lethal drugs. A compassionate platform must tell a transit rider, store worker, parent, and resident which conduct rule applies.

The 2024 Republican platform emphasizes border and law-enforcement action against drug trafficking, especially fentanyl, and public order. It correctly identifies predatory supply and third-party harm. Its exposure is making punishment do work that treatment and regulated markets can do better, and maintaining cannabis prohibition despite widespread state legalization and a live federal rescheduling record.

Libertarian arguments correctly challenge imprisonment for private adult conduct and the violence of prohibited markets. Their exposure is underestimating addiction, marketing power, product information failures, youth protection, impaired operation, and the burdens public use imposes on others. Legalization is a governance beginning, not an absence of governance.

The Green platform calls for ending the drug war, legal cannabis possession and sale, step-by-step decriminalization of all drugs, and legal access to certain entheogens. It correctly treats use and addiction as health questions and recognizes the harms of prohibition. The remaining disagreement is not rhetorical: the Innovation position does not infer from possession decriminalization that a commercial fentanyl or methamphetamine market should exist. Extreme dose risk, adulteration, impaired agency, and transferred harm justify a harder boundary around predatory supply.

Public-health maximalism correctly centers survival, medication, and stigma reduction. Its exposure is using “harm reduction” as though only the participant's immediate risk counts. Neighborhood conditions, coercive dealing, litter, threats, and persistent public use are health and freedom questions too. A pilot that will not measure them asks one group to subsidize another invisibly.

The Innovation Party is distinct in using a risk-and-conduct matrix rather than legalize/prohibit as an identity. It legalizes adult cannabis, decriminalizes other personal possession, prohibits a commercial fentanyl or methamphetamine market, guarantees treatment on a clock, funds overdose response, authorizes bounded pilots, enforces public conduct, and accelerates psychedelic science without opening a wellness free-for-all.

Steelman

The strongest case for prohibition

Legal markets normalize use, expand availability, build firms that lobby for growth, and can create new heavy users. Intoxication harms judgment, health, families, work, and roads. Product innovation can increase potency faster than regulators learn. Decriminalization may weaken the leverage that gets a person into care and signal tolerance while communities face visible disorder. Fentanyl's lethality makes experimentation reckless.

This case justifies strict cannabis product and marketing rules, no lethal-drug retail market, public-conduct enforcement, and revision. It does not establish that a criminal record for personal possession reduces total harm. Prohibition also creates illegal supply, uncertain product, violence, reluctance to seek help, and concentrated enforcement. The platform keeps criminal law where culpability and third-party danger are strongest.

The strongest case for broad legalization

Adults own their bodies. Prohibition transfers wealth to criminal markets, corrupts institutions, creates violence, and fails to prevent access. Legal supply can be tested and taxed. Criminal law punishes users, separates families, and falls unevenly. People already use fentanyl, cocaine, psychedelics, and methamphetamine; regulation could reduce poisoning and allow honest information.

This case defeats possession criminalization and supports cannabis regulation. It does not prove that ordinary retail competition can safely govern substances with extremely narrow dosing, severe dependence, psychosis, or lethal risk. A state dispensary or prescription model for a particular product could be studied in the future, but a general commercial market creates firms whose growth depends on use. The uncertainty burden falls on potential users and communities, so the platform does not authorize it now.

The strongest case against harm-reduction sites

Sites may normalize and concentrate use, attract dealing, burden neighbors, consume money that could fund treatment, and preserve addiction without changing population mortality. Federal law may prohibit maintaining a place for illegal consumption. Staff and emergency responders face risk. Studies often lack strong comparison and measure on-site reversals rather than long-term life.

These objections justify federal authorization, tight operation, exterior management, independent evaluation, neighborhood outcomes, and sunset. They do not justify forbidding every local test when people are dying in bathrooms, alleys, and homes. The site must prove its full effect and cannot claim that an on-site reversal establishes citywide success.

The strongest case against coerced treatment

Treatment imposed through court can violate autonomy, displace voluntary patients, expose medical information, and send people to low-quality programs. Recovery cannot be forced, and relapse can produce punishment rather than care. Families and officials may use “help” to control an unconventional person.

The platform agrees that possession alone does not justify open-ended coercion. It allows mandatory conditions after independently punishable conduct and narrow grave-danger intervention with counsel, evidence, review, time, and real clinical service. The state may restrain acute danger; it may not call confinement treatment because no voluntary system exists.

The strongest case for psychedelic access now

Patients with severe depression, trauma, or addiction cannot wait for slow institutions. Early studies and lived experience show benefit. The compounds may be less physically dangerous than legal substances. Community and traditional use predate modern regulation. Pharmaceutical approval can monopolize access and separate a medicine from the setting that gives it meaning.

This case supports faster research, public funding, state clinical pilots, and protection against unnecessary possession penalties. It does not eliminate expectancy, blinding, adverse-event, exploitation, dose, purity, and durability questions. Desperation makes accurate evidence and ethical boundaries more important because it makes people easier to sell certainty.

Who Bears the Cost

People who use drugs bear overdose, poisoning, dependence, stigma, criminal exposure, privacy loss, and treatment failure. Decriminalization and rescue reduce some burdens. A regulated market can still exploit heavy users, and a civil referral can become coercive in practice.

Families bear grief, caregiving, theft, instability, lost income, child risk, and the exhausting cycle of crisis and refusal. They also bear harm when government offers only arrest or tells them they cannot intervene until a danger becomes catastrophic. The treatment clock and due-process grave-risk standard give them an earlier concrete path without making family allegation sufficient.

Residents, workers, transit riders, and small businesses bear public use, smoke, litter, threats, obstruction, theft, emergency activity, and loss of shared space. They may also face aggressive enforcement and displacement that move rather than resolve the problem. Conduct rules plus usable alternatives recognize both costs.

Crime victims and exploited users bear predatory dealing, adulteration, violence, debt, coercion, and counterfeit product. Focusing enforcement on these acts may require more complex investigation than possession arrests. Public agencies bear the workload; the moral priority justifies it.

People with old records bear exclusion long after a sentence. Automation transfers administrative cost to government, where it belongs. Background firms and agencies bear correction duties. Victims of independent violent conduct retain the record and legal recognition of that harm.

Clinicians, peers, outreach staff, pharmacists, and alternative responders bear workload, burnout, legal uncertainty, safety risk, and moral injury. Capacity, payment, training, privacy, and police backup are required. Moving work from jail to care without funding workers is not reform.

Police bear the complexity of distinguishing possession, sale, public conduct, medical crisis, and danger under new thresholds. Clear statute, training, field guidance, and evidence rules are needed. They should not be judged by possession-arrest volume while leaders publicly claim a health model.

Taxpayers bear regulation, treatment, housing, research, pilots, enforcement, and record repair. They currently bear emergency, incarceration, court, foster-care, health, disability, and lost- productivity costs. The platform does not promise simple savings because successful care may reveal and serve unmet need. Spending is justified by human welfare and public order, then tested for effectiveness.

Cannabis businesses bear compliance and tax. Small firms can be crowded out; weak rules can let large firms externalize public harm. Scaled compliance and anti-concentration review seek a viable lawful market without granting a right to profit from dependence.

The residual cost is moral uncertainty. Some adults will make choices others believe destructive. Some people will refuse help and later die. Some enforcement will be necessary and painful. Some pilots will fail. The state can reduce risk and preserve rescue; it cannot guarantee wise private choice without eliminating liberty.

Cross-Issue Consistency

HEALTH-05 owns the care clock, crisis system, involuntary-intervention safeguards, and recovery pluralism. JUS-03 supplies the legal drug categories and public-order line. It does not invent a weaker addiction-care system inside criminal law.

JUS-01 reforms sentencing, bail, and rehabilitation. Drug penalties follow its opposition to mandatory formulas that ignore role and culpability. Diversion should not become cash bail or an algorithmic risk label under another name.

JUS-02 gives police capacity and accountability. JUS-03 narrows possession work while preserving authority for dangerous conduct and predatory trafficking. Data should show whether officer time moves toward those priorities.

CONST-08 limits excessive fines and punishment. Civil possession responses cannot escalate through debt into jail. Sentences for supply must remain proportionate to role, knowledge, violence, and harm.

CIVIC-01 protects conscience and equal service. Faith-based recovery groups may retain their message, while publicly funded systems ensure an equivalent medication and secular path. A patient's identity or belief cannot determine rescue.

PRIV-01 protects medical, purchase, location, and behavioral data. Treatment linkage and public- health alerts use the minimum necessary information. A decriminalized person should not enter a permanent surveillance registry.

The platform's broader power principle applies to cartel violence, state coercion, corporate marketing, clinical authority, family pressure, and public-health bureaucracy. Every actor must name a purpose, bear evidence, accept limits, and provide remedy.

Methodology & Confidence

OBSERVED, high confidence: CDC's final 2024 mortality data report 79,384 overdose deaths, 54,045 involving any opioid, and 47,735 involving synthetic opioids other than methadone. These are death-certificate statistics with known classification and timing limits; they are not a count of every nonfatal harm.

OBSERVED, high confidence: SAMHSA's 2024 survey estimated 52.6 million people needed substance- use treatment and 10.2 million received it, 19.3 percent of those classified as needing treatment. The cited report defines “need” and “treatment”; those definitions omit or separately classify some services and populations.

OBSERVED, high confidence: cannabis remained listed by DEA as Schedule I while formal Schedule- III rescheduling hearings ran in 2026. Rescheduling and descheduling have different legal effects. Independent counsel should verify status immediately before publication or legislation because the proceeding is live.

OBSERVED, high confidence: FDA approved over-the-counter naloxone and describes it as an overdose-reversal medicine without abuse potential. CDC states medication for opioid-use disorder is associated with reduced overdose and overall mortality and warns against detoxification alone.

OBSERVED, high confidence about agency guidance: FDA has issued psychedelic-trial guidance covering study design, safety, psychotherapy, dose response, abuse, and durability. Guidance does not establish that a psychedelic product is approved or effective for a particular condition.

OBSERVED, moderate confidence: supervised-consumption sites can reverse onsite overdose and connect participants to services. Evidence on population mortality is mixed and context dependent. The 2026 systematic review included six studies, all in Canada, and called for more rigorous work. U.S. pilots need their own evaluation.

PROJECTED, moderate confidence: cannabis descheduling with strict national floors will reduce legal incoherence and illicit-market share without producing net public-health harm. Outcome depends on price, tax, product, advertising, enforcement, concentration, and state practice. The policy includes revision because direction and magnitude are not guaranteed.

PROJECTED, moderate confidence: possession decriminalization paired with scheduled treatment, public-conduct enforcement, and capacity will reduce criminal harm without increasing disorder. Oregon shows that pairing and execution are decisive. Causal confidence about any single state outcome is limited by concurrent fentanyl, housing, pandemic, and implementation changes.

NORMATIVE: adult cannabis legalization, personal-possession decriminalization, no commercial fentanyl or methamphetamine market, enforcement against public harmful conduct, automatic record repair, and the allocation of uncertainty in psychedelic access are moral and political judgments. Evidence informs the tools but does not choose the liberty boundary.

UNCERTAIN: optimal possession thresholds, cannabis potency tax, per se impairment measures, long-run market effects, best supervised-site model, and which psychedelic service designs produce durable net benefit. These need primary research and periodic rulemaking rather than false finality.

The issue remains ai-researched-unverified. Legal review should cover the Controlled Substances Act, Commerce Clause, spending conditions, FDA law, state and tribal authority, impaired-driving evidence, employment, disability, privacy, sentencing, supervised-site law, and record relief. Clinical and statistical reviewers should audit outcome claims and causal language. People with addiction, recovery experience, chronic pain, and neighborhood exposure should review the operating assumptions, not merely the rhetoric.

Citations

• CDC National Center for Health Statistics, Drug Overdose FastStats — final 2024 mortality totals for all drug overdoses, opioids, and synthetic opioids.
• SAMHSA, Key Substance Use and Mental Health Indicators in the United States: Results from the 2024 National Survey on Drug Use and Health — national treatment-need, receipt, and substance-use estimates with definitions.
• DEA, Marijuana Rescheduling Regulatory Actions — live federal docket and 2026 hearing record for proposed transfer from Schedule I to Schedule III.
• DEA, Controlled Substances Act overview — official scheduling authority, factors, and procedure.
• DEA, Drug Scheduling — current public schedule descriptions and cannabis listing used to verify legal status.
• CDC, Opioid Use Disorder: Treating — federal clinical summary on medications, mortality, and the risk of detoxification alone.
• FDA, first approval of over-the-counter naloxone nasal spray — approval record and agency explanation of naloxone's overdose-reversal role.
• CDC, Overdose Data to Action prevention strategies — federal framework for linkage to evidence-based care and harm-reduction services.
• CDC, Opioid Rapid Response Program — current federal coordination model for mitigating overdose risk after controlled-substance care disruption.
• FDA, Psychedelic Drugs: Considerations for Clinical Investigations — primary federal guidance on psychedelic trial design, safety, psychotherapy, and evidence.
• Public Health Agency of Canada authors, 2026 systematic review of supervised-consumption sites and population mortality — finds mixed and context-dependent population-level evidence and identifies research limits.
• Stanford-Lancet Commission report available through CDC Stacks — broader opioid-policy review, including a cautious assessment of supervised-consumption evidence.
• Oregon House Bill 4002, 2024 Regular Session — official legislative record for Oregon's revised possession and deflection framework.
• 2024 Democratic Party Platform — official party positions used for comparison.
• 2024 Republican Party Platform — official party positions used for comparison.
• Libertarian Party Platform — official position against drug-use crimes and for adult self-ownership used in comparison.
• Green Party Social Justice Platform — official positions on cannabis, drug decriminalization, treatment, and entheogens used in comparison.